Cancer Profiling Market

Cancer Profiling Market Share & Analysis – Industry Overview

Base Year: 2024 Historical Data: 2021-23
  • Report ID: TBI-14704
  • Published Date: Apr, 2025
  • Pages: 237
  • Category: Healthcare
  • Format: PDF
Buy @ $4700.00 Request Sample PDF

Segment Analysis

Regional segmentation analysis

The regions analyzed for the market include North America, Europe, South America, Asia Pacific, the Middle East, and Africa. North America emerged as the most significant global cancer profiling market, with a 41% market revenue share in 2024.

The region has advanced healthcare systems which treat many cancer cases while prioritizing precise medicine methods. Cancer profiling solution markets are predominantly led by United States and Canada because both countries have fully developed systems for molecular diagnostics drug development and cancer research focused on biomarkers. The main reason behind North America’s leadership position in the global cancer profiling sector stems from its large number of individuals afflicted with cancer. New market growth stems from robust investments conducted by both public institutions and private corporations. Market adoption increases through regulatory approvals of NGS-based tests together with companion diagnostics. Medical innovation in personalized oncology advances rapidly through joint endeavours of research centres with pharmaceutical companies as well as healthcare institutions. The North American market maintains its leadership position in global cancer profiling because genomics technology continues advancing together with AI-driven diagnostic systems.

North America Region Cancer Profiling Market Share in 2024 - 41%

 

www.thebrainyinsights.com

Check the geographical analysis of this market by requesting a free sample

  • In the United States, xT CDx, an in vitro diagnostic tool based on next-generation sequencing (NGS), is now accessible statewide for solid tumour profiling. For solid tumour profiling, including microsatellite instability status and companion diagnostic claims for patients with colorectal cancer (CRC), the FDA authorised xT CDx, a 648-gene NGS assay.  The in vitro diagnostic device detects substitutions, including single nucleotide variants (SNVs) and multi-nucleotide variants (MNVs), as well as insertion/deletion alterations in 648 genes using DNA isolated from FFPE tumour tissue samples and DNA isolated from matched normal blood or saliva samples obtained from patients diagnosed with solid malignant neoplasms.

Technology Segment Analysis

The technology segment is divided into Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Microarrays and Others. The Next-Generation Sequencing (NGS) segment dominated the market, with a market share of around 35% in 2024. The cancer profiling market leads with Next-Generation Sequencing (NGS) due to its precise large-scale analysis of simultaneous gene evaluation. Personalized cancer care based on precision medicine becomes feasible through the genomic insights made possible by NGS instead of using obsolete sequencing approaches like Sanger sequencing and PCR. The extensive use of NGS technology mainly results from its ability to help choose targeted therapies. Large-sequence analysis with NGS proves cheaper than conventional techniques for sequencing programs. The technological progress in laboratory automation together with reduced sequencing expenses has driven clinical laboratories and research institutions to choose NGS for cancer profiling. The market penetration of NGS-based companion diagnostics intensified due to regulatory approvals by the FDA and EMA along with other authorities.

Cancer type Segment Analysis

The cancer type segment is divided into breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma and others. The breast cancer segment dominated the market, with a market share of around 33% in 2024. The cancer profiling market is dominated by breast cancer patients because it has the highest worldwide incidence rates. Breast cancer stands as the WHO-recognized leading cancer form worldwide because thousands of individuals receive breast cancer diagnoses every year globally. The rising cancer incidence has made cancer profiling necessary because this approach provides essential support for timely detection and treatments. The introduction of breast cancer-targeted medications along with PARP inhibitors for patients with BRCA-mutations creates additional medical need for breast cancer profiling. The rise in breast cancer screening activities along with public awareness initiatives lead to increased adoption of molecular profiling. Breast cancer detection rates have increases elevated because government entities and healthcare institutions run routine screening programs that involve mammography and genetic evaluation.

  • The launch of PANProfiler Colon, an AI-driven software solution for profiling Microsatellite instability (MSI) and mismatch repair deficiency (dMMR) entirely digitally and directly from Haematoxylin and Eosin (H&E)-stained images of colon cancer tissue samples, was announced by Panakeia, a leader in AI-driven multi-omic biomarker profiling.  The second clinical product from Panakeia's PANProfiler multi-omic biomarker profiling technology, PANProfiler Colon, uses artificial intelligence (AI) and exclusive knowledge of colorectal cancer biology.  While the PANProfiler platform is accessible for Research Use Only (RUO) and can profile biomarkers in more than 30 cancer types for patient screening and clinical trials, PANProfiler Colon is registered for use in the UK (UKCA-marked).

Biomarker type Segment Analysis

The biomarker type segment is divided into genetic biomarkers, protein biomarkers, epigenetic biomarkers and others. The genetic biomarkers segment dominated the market, with a market share of around 40% in 2024. The cancer profiling market primarily uses genetic biomarkers because these biomarkers play essential roles in precision medicine, early detection and selecting specific therapeutic approaches. The specific and sensitive nature of genetic biomarkers makes them the selection preference for oncologists and researchers above protein and epigenetic biomarkers. Next-Generation Sequencing (NGS) and Polymerase Chain Reaction (PCR) with liquid biopsy technologies have expanded the success of genetic biomarkers through their ongoing technological improvements. The combination of these technical methods enables rapid cost-efficient genetic screening from blood as well as tissue samples which increases cancer diagnosis capabilities. The FDA along with EMA granted regulatory approval for NGS-based companion diagnostics which boosted the implementation of genetic biomarkers throughout medical practice. The profiling market for cancer will be led by genetic biomarkers because scientists continue their investigation of new oncogenic mutations.

Application Segment Analysis

The application segment is divided into diagnostics, prognostics, personalized medicine, drug development and others. The diagnostics segment dominated the market, with a share of around 42% in 2024. Cancer profiling functions as an essential tool for medical practitioners to determine genetic mutations along with biomarkers and molecular patterns which affect disease advancement and therapeutic selection processes. The rising global incidence of cancer together with an increased desire for sophisticated diagnostic instruments has led to substantial growth because early disease detection creates better outcomes for patients. Routine cancer screening together with diagnostic features has established molecular profiling as the dominant factor in medical diagnostics practice. The market has experienced expansion due to governmental programs together with biomarker-based cancer diagnostic approval processes. The FDA along with the EMA approved various diagnostic tests that can now be routinely used for standard care in oncology. The development of precision medicine will keep fuelling the growing market need for cancer profiling diagnostics so they become increasingly dominant across worldwide cancer diagnostics.

End user Segment Analysis

The end user segment is divided into hospitals & diagnostic laboratories, pharmaceutical & biotechnology companies and academic & research institutes. The hospitals & diagnostic laboratories segment dominated the market, with a share of around 43% in 2024. Hospitals and laboratories maintain their position as primary user facilities for cancer profiling solutions as they have access to advanced diagnostic technologies along with specialized oncologists who support their access to large numbers of cancer patients. Hospitals together with diagnostic laboratories gain access to governmental financial support along with payments from insurance providers and pharmaceutical company partnerships which contribute to precision oncology development. Many research hospitals work together with biotech firms to develop new biomarker-based tests for medical markets through validation processes and increase industry expansion. The combination of infrastructure capabilities and technical expertise coupled with advanced technological access keeps hospitals and diagnostic laboratories as the top players in the global cancer profiling market.

  • With CAP (College of American Pathologists) accreditation for its genomics lab at Dubai Science Park, which was built in collaboration with Innovate Life Sciences Fz-LLC, 4baseCare, a pioneer in precision oncology, has reached a significant milestone. Thanks to this accreditation, cancer patients in the United Arab Emirates can now receive top-notch genomic profiling locally that satisfies the strictest international quality and accuracy requirements.  4baseCare reinforces its dedication to improving cancer care by making data-driven, individualised treatment decisions by obtaining CAP accreditation.  The laboratory in Dubai fills a significant void in precision oncology by removing the requirement for patients to look for genomic testing options outside of the United Arab Emirates.

Request Table of Content

+1

This study forecasts revenue at global, regional, and country levels from 2021 to 2034. The Brainy Insights has segmented the global cancer profiling market based on below mentioned segments:

Global Cancer profiling Market by Technology:

  • Next-Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Immunohistochemistry (IHC)
  • In Situ Hybridization (ISH)
  • Microarrays
  • Others

Global Cancer profiling Market by Cancer Type:

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Melanoma
  • Others

Global Cancer profiling Market by Biomarker Type:

  • Genetic Biomarkers
  • Protein Biomarkers
  • Epigenetic Biomarkers
  • Others

Global Cancer profiling Market by Application:

  • Diagnostics
  • Prognostics
  • Personalized Medicine
  • Drug Development
  • Others

Global Cancer profiling Market by End-User:

  • Hospitals & Diagnostic Laboratories
  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutes

Global Cancer profiling Market by Region:

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
  • Asia-Pacific
    • Japan
    • China
    • India
  • South America
    • Brazil
  • Middle East and Africa  
    • UAE
    • South Africa

Methodology

Research has its special purpose to undertake marketing efficiently. In this competitive scenario, businesses need information across all industry verticals; the information about customer wants, market demand, competition, industry trends, distribution channels etc. This information needs to be updated regularly because businesses operate in a dynamic environment. Our organization, The Brainy Insights incorporates scientific and systematic research procedures in order to get proper market insights and industry analysis for overall business success. The analysis consists of studying the market from a miniscule level wherein we implement statistical tools which helps us in examining the data with accuracy and precision. 

Our research reports feature both; quantitative and qualitative aspects for any market. Qualitative information for any market research process are fundamental because they reveal the customer needs and wants, usage and consumption for any product/service related to a specific industry. This in turn aids the marketers/investors in knowing certain perceptions of the customers. Qualitative research can enlighten about the different product concepts and designs along with unique service offering that in turn, helps define marketing problems and generate opportunities. On the other hand, quantitative research engages with the data collection process through interviews, e-mail interactions, surveys and pilot studies. Quantitative aspects for the market research are useful to validate the hypotheses generated during qualitative research method, explore empirical patterns in the data with the help of statistical tools, and finally make the market estimations.

The Brainy Insights offers comprehensive research and analysis, based on a wide assortment of factual insights gained through interviews with CXOs and global experts and secondary data from reliable sources. Our analysts and industry specialist assume vital roles in building up statistical tools and analysis models, which are used to analyse the data and arrive at accurate insights with exceedingly informative research discoveries. The data provided by our organization have proven precious to a diverse range of companies, facilitating them to address issues such as determining which products/services are the most appealing, whether or not customers use the product in the manner anticipated, the purchasing intentions of the market and many others.

Our research methodology encompasses an idyllic combination of primary and secondary initiatives. Key phases involved in this process are listed below:

MARKET RESEARCH PROCESS

Data Procurement:

The phase involves the gathering and collecting of market data and its related information with the help of different sources & research procedures.

The data procurement stage involves in data gathering and collecting through various data sources.

This stage involves in extensive research. These data sources includes:

Purchased Database: Purchased databases play a crucial role in estimating the market sizes irrespective of the domain. Our purchased database includes:

  • The organizational databases such as D&B Hoovers, and Bloomberg that helps us to identify the competitive scenario of the key market players/organizations along with the financial information.
  • Industry/Market databases such as Statista, and Factiva provides market/industry insights and deduce certain formulations. 
  • We also have contractual agreements with various reputed data providers and third party vendors who provide information which are not limited to:
    • Import & Export Data
    • Business Trade Information
    • Usage rates of a particular product/service on certain demographics mainly focusing on the unmet prerequisites

Primary Research: The Brainy Insights interacts with leading companies and experts of the concerned domain to develop the analyst team’s market understanding and expertise. It improves and substantiates every single data presented in the market reports. Primary research mainly involves in telephonic interviews, E-mail interactions and face-to-face interviews with the raw material providers, manufacturers/producers, distributors, & independent consultants. The interviews that we conduct provides valuable data on market size and industry growth trends prevailing in the market. Our organization also conducts surveys with the various industry experts in order to gain overall insights of the industry/market. For instance, in healthcare industry we conduct surveys with the pharmacists, doctors, surgeons and nurses in order to gain insights and key information of a medical product/device/equipment which the customers are going to usage. Surveys are conducted in the form of questionnaire designed by our own analyst team. Surveys plays an important role in primary research because surveys helps us to identify the key target audiences of the market. Additionally, surveys helps to identify the key target audience engaged with the market. Our survey team conducts the survey by targeting the key audience, thus gaining insights from them. Based on the perspectives of the customers, this information is utilized to formulate market strategies. Moreover, market surveys helps us to understand the current competitive situation of the industry. To be precise, our survey process typically involve with the 360 analysis of the market. This analytical process begins by identifying the prospective customers for a product or service related to the market/industry to obtain data on how a product/service could fit into customers’ lives.

Secondary Research: The secondary data sources includes information published by the on-profit organizations such as World bank, WHO, company fillings, investor presentations, annual reports, national government documents, statistical databases, blogs, articles, white papers and others. From the annual report, we analyse a company’s revenue to understand the key segment and market share of that organization in a particular region. We analyse the company websites and adopt the product mapping technique which is important for deriving the segment revenue. In the product mapping method, we select and categorize the products offered by the companies catering to domain specific market, deduce the product revenue for each of the companies so as to get overall estimation of the market size. We also source data and analyses trends based on information received from supply side and demand side intermediaries in the value chain. The supply side denotes the data gathered from supplier, distributor, wholesaler and the demand side illustrates the data gathered from the end customers for respective market domain.

The supply side for a domain specific market is analysed by:

  • Estimating and projecting penetration rates through analysing product attributes, availability of internal and external substitutes, followed by pricing analysis of the product.
  • Experiential assessment of year-on-year sales of the product by conducting interviews.

The demand side for the market is estimated through:

  • Evaluating the penetration level and usage rates of the product.
  • Referring to the historical data to determine the growth rate and evaluate the industry trends

In-house Library: Apart from these third-party sources, we have our in-house library of qualitative and quantitative information. Our in-house database includes market data for various industry and domains. These data are updated on regular basis as per the changing market scenario. Our library includes, historic databases, internal audit reports and archives.

Sometimes there are instances where there is no metadata or raw data available for any domain specific market. For those cases, we use our expertise to forecast and estimate the market size in order to generate comprehensive data sets. Our analyst team adopt a robust research technique in order to produce the estimates:

  • Applying demographic along with psychographic segmentation for market evaluation
  • Determining the Micro and Macro-economic indicators for each region 
  • Examining the industry indicators prevailing in the market. 

Data Synthesis: This stage involves the analysis & mapping of all the information obtained from the previous step. It also involves in scrutinizing the data for any discrepancy observed while data gathering related to the market. The data is collected with consideration to the heterogeneity of sources. Robust scientific techniques are in place for synthesizing disparate data sets and provide the essential contextual information that can orient market strategies. The Brainy Insights has extensive experience in data synthesis where the data passes through various stages:

  • Data Screening: Data screening is the process of scrutinising data/information collected from primary research for errors and amending those collected data before data integration method. The screening involves in examining raw data, identifying errors and dealing with missing data. The purpose of the data screening is to ensure data is correctly entered or not. The Brainy Insights employs objective and systematic data screening grades involving repeated cycles of quality checks, screening and suspect analysis.
  • Data Integration: Integrating multiple data streams is necessary to produce research studies that provide in-depth picture to the clients. These data streams come from multiple research studies and our in house database. After screening of the data, our analysts conduct creative integration of data sets, optimizing connections between integrated surveys and syndicated data sources. There are mainly 2 research approaches that we follow in order to integrate our data; top down approach and bottom up approach.

Market Deduction & Formulation: The final stage comprises of assigning data points at appropriate market spaces so as to deduce feasible conclusions. Analyst perspective & subject matter expert based holistic form of market sizing coupled with industry analysis also plays a crucial role in this stage.

This stage involves in finalization of the market size and numbers that we have collected from data integration step. With data interpolation, it is made sure that there is no gap in the market data. Successful trend analysis is done by our analysts using extrapolation techniques, which provide the best possible forecasts for the market.

Data Validation & Market Feedback: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helps us finalize data-points to be used for final calculations.

The Brainy Insights interacts with leading companies and experts of the concerned domain to develop the analyst team’s market understanding and expertise. It improves and substantiates every single data presented in the market reports. The data validation interview and discussion panels are typically composed of the most experienced industry members. The participants include, however, are not limited to:

  • CXOs and VPs of leading companies’ specific to sector
  • Purchasing managers, technical personnel, end-users
  • Key opinion leaders such as investment bankers, and industry consultants

Moreover, we always validate our data and findings through primary respondents from all the major regions we are working on.

Some Facts About The Brainy Insights

50%

Free Customization

300+

Fortune 500 Clients

1

Free Yearly Update On Purchase Of Multi/Corporate License

900+

Companies Served Till Date